{
    "clinical_study": {
        "@rank": "144754", 
        "acronym": "GO-COLITIS", 
        "arm_group": {
            "arm_group_label": "Golimumab", 
            "arm_group_type": "Experimental", 
            "description": "The first dose of subcutaneous (SC) golimumab 200 mg will be administered at Visit 2 (Day 0). The second induction dose of SC golimumab 100 mg will be administered two weeks later at Visit 3 (Week 2). Responders at Visit 4 (Week 6) will receive a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight \u226580 kg) during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the efficacy of golimumab in maintaining\n      a clinical response in participants with moderate-to-severe ulcerative colitis."
        }, 
        "brief_title": "Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study consists of a 1 week screening period, a 54 week treatment period, and a 12 week\n      follow-up period, requiring a total of 7 in trial site visits: Visit 1(screening visit, Week\n      -1), Visit 2 (enrollment visit, Day 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 5 (Week\n      30) and Visit 6 (Week 54) and Visit 7 (follow-up visit, Week 66)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of ulcerative colitis for at least 3 months prior to enrollment.\n\n          -  Has a rectal bleeding subscore of 1 or more at baseline.\n\n          -  No evidence of active, or latent, or inadequately treated infection with\n             Mycobacterium tuberculosis (TB).\n\n          -  Must be eligible to start golimumab treatment according to the summary of product\n             characteristics.\n\n          -  Must be na\u00efve to anti-tumor necrosis factor (anti-TNF) therapy.\n\n          -  Women of childbearing potential or men capable of fathering children must agree to\n             use adequate birth control measures (eg, abstinence, oral contraceptives,\n             intrauterine device, barrier method with spermicide, implant, surgical\n             sterilization).\n\n          -  Women of childbearing potential must test negative for pregnancy at screening and at\n             Week 0.\n\n          -  Has been on azathioprine (6-mercaptopurine) for at least 12 weeks, and stable for 4\n             weeks prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  Clinical signs of ischaemic colitis, fulminant colitis or toxic megacolon.\n\n          -  Has evidence of pathogenic bowel infection.\n\n          -  Has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's\n             disease.\n\n          -  Has had surgery as a treatment for ulcerative colitis, or is likely to require\n             surgery.\n\n          -  Has ulcerative colitis which is confined to a proctitis (distal 15 cm or less).\n\n          -  Has a current or recent history of severe, progressive, or uncontrolled renal,\n             hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac,\n             or neurological disease.\n\n          -  Has a current immunization with any live virus vaccine or history of immunization\n             with any live virus vaccine within 3 months of baseline.\n\n          -  Pregnant or lactating, or planning pregnancy while enrolled in the study.\n\n          -  Has received agents that deplete B or T cells (eg, rituximab or alemtuzumab) within\n             12 months prior to study inclusion, or continue to manifest depletion of B or T cells\n             more than 12 months after completion of therapy with lymphocyte-depleting agents.\n\n          -  Has received cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF)\n             within 8 weeks prior to study inclusion.\n\n          -  Has used any investigational drugs within 30 days of Screening.\n\n          -  Has a known hypersensitivity to human immunoglobulin proteins or other components of\n             golimumab. during the study period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092285", 
            "org_study_id": "8259-032", 
            "secondary_id": "2013-004583-56"
        }, 
        "intervention": {
            "arm_group_label": "Golimumab", 
            "intervention_name": "Golimumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "number_of_arms": "1", 
        "official_title": "Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis", 
        "overall_contact": {
            "email": "ClinicalTrialsDisclosure@merck.com", 
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Participants Meeting Partial Mayo Score Response Criteria at Week 54", 
            "safety_issue": "No", 
            "time_frame": "Week 54"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}